#United States #Fort Lee #Kedrion Biopharma #Grifols #GAMMAKED

Kedrion Biopharma Extends Agreement with Grifols for GAMMAKED®

Kedrion Biopharma, a prominent player in the biopharmaceutical industry that focuses on therapies for rare and serious diseases, recently unveiled a significant extension of its agreement with Grifols. This strategic move is centered around promoting continued access to GAMMAKED® (Immune Globulin Injection), a critical IVIG therapy specifically designed for patients grappling with chronic and serious medical conditions.

This renewed partnership reinforces both companies' commitment to maintaining broad access to GAMMAKED® for individuals suffering from primary immunodeficiency, idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). These conditions demand consistent treatment to provide patients with the necessary support and management, making a reliable supply of GAMMAKED® essential for effective disease management.

Ugo Di Francesco, CEO of Kedrion Biopharma, highlighted the importance of this collaboration: "Our long-standing relationship with Grifols reflects a shared commitment to ensuring patients continue to have access to the therapies they depend on. Our collaboration significantly strengthens our efforts in the U.S. market, reinforcing our dedication to investing in treatments and partnerships that cater to individuals with serious and chronic conditions."

This partnership builds on a successful track record exceeding a decade, during which Kedrion has been marketing and distributing GAMMAKED® across the United States. This established relationship not only enhances the company’s presence but also provides physicians and healthcare providers a reliable choice of treatment options, while maintaining vital access for patients.

Bob Rossilli, the Chief Commercial Officer at Kedrion Biopharma, made a crucial point regarding the effective delivery of therapies: "Innovation doesn't end with developing effective therapies. Delivering those therapies consistently and reliably is equally important. Our focus is on having a dependable supply network that healthcare providers can count on to keep a growing patient population on therapy without interruption."

By securing this agreement, Kedrion Biopharma is poised to fortify its position in the U.S. market while ensuring that vital treatments remain accessible to those in need. As the healthcare landscape evolves, the importance of such partnerships becomes ever more pronounced, emphasizing the ongoing responsibility to prioritize patient access to essential medical therapies.

About GAMMAKED®

GAMMAKED® is vital for treating primary humoral immunodeficiency (PI) in patients aged two and older, ITP in both adults and children, and CIDP in adults. The product is derived from human plasma and is instrumental in managing conditions that significantly impact patients’ quality of life.

While the benefits of GAMMAKED® are profound, it is essential to remain vigilant regarding potential side effects. Adverse reactions can include headaches, fever, and various other symptoms. Therefore, the administration of GAMMAKED® must be conducted with care, particularly for patients who may be at risk of renal issues or have a history of thrombosis.

In summary, the extension of the partnership between Kedrion Biopharma and Grifols marks a pivotal moment in the healthcare sector, as the emphasis on ensuring ongoing access to life-saving therapies continues to play a crucial role in the management of rare and serious conditions across the United States.